Syros Pharmaceuticals Inc (NASDAQ: SYRS) is -95.39% lower on its value in year-to-date trading and has touched a low of $1.43 and a high of $8.17 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The SYRS stock was last observed hovering at around $2.73 in the last trading session, with the day’s loss setting it -2.37%.
Currently trading at $0.36, the stock is -84.31% and -82.42% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 38.11 million and changing -86.85% at the moment leaves the stock -92.12% off its SMA200. SYRS registered -86.65% loss for a year compared to 6-month loss of -93.48%. The firm has a 50-day simple moving average (SMA 50) of $2.0657 and a 200-day simple moving average (SMA200) of $4.590275.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -81.96% gain in the last 1 month and extending the period to 3 months gives it a -76.54%, and is -85.35% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 16.64% over the week and 14.14% over the month.
Syros Pharmaceuticals Inc (SYRS) has around 68 employees, a market worth around $9.63M and $0.39M in sales. Profit margin for the company is -25340.67%. Distance from 52-week low is -74.90% and -95.61% from its 52-week high. The company has generated returns on investments over the last 12 months (-210.27%).
The EPS is expected to grow by 73.32% this year
85.0 institutions hold shares in Syros Pharmaceuticals Inc (SYRS), with institutional investors hold 82.81% of the company’s shares. The shares outstanding are 26.45M, and float is at 19.70M with Short Float at 6.34%. Institutions hold 80.88% of the Float.
Syros Pharmaceuticals Inc (SYRS) Insider Activity
The most recent transaction is an insider purchase by Chee Conley, the company’s President & CEO. SEC filings show that Chee Conley bought 50,000 shares of the company’s common stock on Sep 11 ’24 at a price of $1.71 per share for a total of $85420.0. Following the purchase, the insider now owns 0.12 million shares.
Syros Pharmaceuticals Inc disclosed in a document filed with the SEC on Sep 12 ’24 that Haas Jason (Chief Financial Officer) bought a total of 45,344 shares of the company’s common stock. The trade occurred on Sep 12 ’24 and was made at $1.68 per share for $76006.0. Following the transaction, the insider now directly holds 0.12 million shares of the SYRS stock.
Still, SEC filings show that on Sep 10 ’24, Chee Conley (President & CEO) acquired 50,000 shares at an average price of $1.51 for $75260.0. The insider now directly holds 72,504 shares of Syros Pharmaceuticals Inc (SYRS).
